CBT-005

N/A

Report date: 2025/09/25 10:08:54

Base Information

Drug NameCBT-005
Drug Alias NameCBT-005
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionVascular endothelial growth factor A inhibitorsVascular endothelial growth factor receptor antagonists
TargetsVascular endothelial growth factor AVascular endothelial growth factor receptor
Therapy Area/IndicationsMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCloudbreak Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCloudbreak Therapeutics Llc
Active IndicationsN/A
Inactive IndicationsMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A